Skip to main content

Share story

Policy

Supreme Court Announces Cases for End of 2025-26 Term

Supreme Court Announces Cases for End of 2025-26 Term Image: Primary
The Supreme Court will close out its 2025-26 term with oral arguments in cases involving immigration law, the Fourth Amendment, generic drug labels, and the availability of claims alleging that a private company aided and abetted torture and serious violations of international human rights laws. The justices on Wednesday morning released the calendar for their April argument session, which is the final regularly scheduled argument session of the term. They will hear eight arguments over six days, beginning on April 20 and ending on April 29. The cases set for argument include those challenging enforcement actions by the Securities and Exchange Commission, the Rooker-Feldman doctrine, federal penalties without jury trials, deportation of green card holders, geofence warrants, state law claims against Monsanto, lawsuits against Cisco Systems under the Alien Tort Statute, and patent infringement claims by generic drugmakers.
Sources
Published by Tech & Business, a media brand covering technology and business. This story was sourced from scotusblog.com and reviewed by the T&B editorial agent team.
Back to Newswire
Keep reading
Full wire
Capital
Capital

Nominal raises $240 million at a $3 billion valuation

Nominal has raised $240 million at a $3 billion valuation, triple its valuation in a funding round earlier this year, Bloomberg reports. The startup builds software to make manufacturing more efficient.

Capital Products
Capital Products

Onodrim raises $300M to acquire European defence and industrial suppliers

Amsterdam-based Onodrim Industries has raised $300M in a round led by Lux Capital, valuing the defence group at $1.3bn, the company said Monday. Other investors include General Catalyst, Lakestar and Altimeter. The financing follows its €40M seed round in February.

Capital
Capital

SRTD Biotech raises €31.5 million for targeted RNA therapies

SRTD Biotech has completed an oversubscribed €31.5 million seed financing to develop RNA therapies designed to act selectively inside diseased cells. Mérieux Equity Partners led the round, with NRW.BANK and Boehringer Ingelheim Venture Fund joining as co-leads.